Awaya N, Takao M, Natsuda H, Yamawaki T, Suzuki N, Takayama N, Ishida A, Kawai Y
Department of Internal Medicine, Mito Red Cross Hospital, Japan.
Rinsho Ketsueki. 1995 Nov;36(11):1300-4.
A 57-year-old female was diagnosed being in the blastic phase of chronic myelogenous leukemia (CML) on her second admission in May 1993. The patient was previously treated with vincristine and prednisolone in the accelerated phase of CML in December 1991 without improvement. Other chemotherapeutic agents such as BHAC-DMP (enocitabine, daunorubicin, mercaptopurine, prednisolone), interferon, mercaptopurine and ranimustine were also administered. After the second chronic phase was achieved, she was treated with busulfan as an outpatient. On her second admission, the diagnosis of erythroblastic transformation was made, and cytogenetic study revealed t(9;22) (q34;q11) with the additional chromosomal abnormalities, t(6;9) (p23;q34). This karyotype rearrangement has been reported neither in Ph-positive CML nor in blastic crisis.
一名57岁女性于1993年5月第二次入院时被诊断为慢性粒细胞白血病（CML）急变期。该患者曾于1991年12月在CML加速期接受长春新碱和泼尼松龙治疗，但病情无改善。还使用了其他化疗药物，如BHAC-DMP（依诺他滨、柔红霉素、巯嘌呤、泼尼松龙）、干扰素、巯嘌呤和雷莫司汀。在达到第二次慢性期后，她作为门诊患者接受了白消安治疗。第二次入院时，诊断为红系转化，细胞遗传学研究显示t(9;22) (q34;q11)，伴有额外的染色体异常t(6;9) (p23;q34)。这种核型重排在Ph阳性CML或急变期均未见报道。
